[Clinical experience with daily doses of misonidazole (author's transl)].
In this pilot study daily low doses of misonidazole (in the range of 1 to 2 g) up to cumulative doses between 7 and 19 g/m2 were used. Serum levels were analysed at different times after administration and according to several dose regimens. We related the cumulative doses to the incidence and severity of the observed peripheral neuropathies. The aim was to find an effective daily low-dose schedule of misonidazole with a clinically acceptable incidence of side effects. Some impressive clinical responses were observed.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D008920:Misonidazole / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D009420:Nervous System / Q000187:drug effects; D009593:Nitroimidazoles / Q000008:administration & dosage*; D013997:Time Factors
D009593:Nitroimidazoles; D008920:Misonidazole
Klinische Erfahrungen bei täglicher Gabe von Misonidazol.